Skip to main content
SpringerLink
Log in

Monoclonal antibodies in neuro-oncology

  • Invited Article
  • Published:
Neurosurgical Review Aims and scope Submit manuscript

Abstract

Many studies have suggested the possible existence of tumor-associated antigens in brain gliomas. Strong evidence for the existence of such cell determinants was provided by recent investigations using hybridoma technology. The possibility of obtaining monoclonal antibodies (MAbs) against glioma-associated antigens should help to allow their identification, purification, and characterization.

Utilizing MAbs as reagents of predefined specificity, a number of central and peripheral nervous system antigens could be detected. The molecules recognized by MAbs in glioma cells can be subdivided into four categories: [1] biochemical defined proteins, [2] specificities shared by nervous system-lymphoid cells, [3] oncoembryonic-oncofetal determinants, and [4] tumor-restricted antigens. Of greater significance is the heterogeneity of antigen expression among various individual glioma cells observed in frozen sections of tumor biopsies. Using a panel of MAbs, the phenotypic heterogeneity, i.e., the variation in antigen expression can be documented within and among malignant gliomas and cell lines derived from them. In spite of this the characteristic pattern of antibody binding to brain tumors makes MAbs the potentially best reagents for immuno-histochemical application in surgical neuropathology. Moreover, immuno-cytological screening of tumor cells in the cerebrospinal fluid has also proved to be valuable.

The localization of radio-labelled MAbs in experimental and human gliomas growing subcutaneously and intracranially in athymic nude mice were explored by radioscintigraphy and autoradiography. Imaging experiments with131I-labelled MAbs recognizing epitopes on the glioma cell surface showed high levels of specific activity in xenografts. Preliminary data indicate that administration of131I-MAbs as well as drug conjugates (daunomycin-MAbs) causes a depression of glioma cell proliferation in vitro as well as delayed tumor growth and thus prolonged survival time of tumor-bearing mice. The mechanisms of antibody delivery and transport of “immunotoxins” from the vascular compartment to intracerebral tumor tissue are presently a subject of discussion. The complexity of this area necessitates comprehensive experimental work in order to define the factors involved in the delivery of MAbs to brain tumor tissue and thus optimize the rate of blood-to-tumor transport. Current investigations have shown that it is possible to image malignant human gliomas using radio-labelled antibodies. The next step will be to attain target immunotherapy. The use of MAbs as carrier molecules for clinical applications might soon be possible.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ballou B, G Levin, RR Hakala, D Solter: Tumor location detected with radioactivity labeled monoclonal antibody and external scintigraphy. Science 206 (1979) 844–847

    Google Scholar 

  2. Bergh J, S Nilsson, D Stavrou, E Maripuu, A Epenetos: In vivo localization of human malignant gliomas utilizing an indium labelled monoclonal antibody (MUC 2-63). Abstracts of the 2nd Int. Conf. of Anticancer Res. Saronis, Greece Oct. 11–15 1988

  3. Bigner D, S Bigner, J Ponten, B Westermark, M Mahaley, E Ruoslahti, H Herschman, L Eng, C Wirkstrand: Heterogeneity of genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas. J Neuropathol Exp Neurol 40 (1981) 201–229

    Google Scholar 

  4. Bigner S, J Mark, D Bigner: Chromosomal composition of four permanent cultured cell lines derived from human gliomas. Cancer Genet Cytogenet 2 (1983) 335–351

    Google Scholar 

  5. Bigner S, P Burger, J Mark, D Bullard, D Bigner: Relationship beteeen karyotype and histologic parameters of malignant human gliomas. J Neuropathol Exp Neurol 43 (1984) 335

    Google Scholar 

  6. Bourdon MA, RE Coleman, RG Blasberg, DR Groothuis, DD Bigner: Monoclonal antibody localization in subcutaneous and intracranial human glioma xenografts: Paired-label and imaging analysis. Anticancer Res 4 (1984) 133–140

    Google Scholar 

  7. Bullard DE, DD Bigner: Applications of monoclonal antibodies in the diagnosis and treatment of primary brain tumors. J Neurosurg 63 (1985) 2–16

    Google Scholar 

  8. Bullard DE, CJ Adams, RE Coleman, DD Bigner: In vivo imaging of intracranial human glioma xenografts comparing specific with non specific radiolabeled monoclonal antibodies. J Neurosurg 64 (1986) 257–262

    Google Scholar 

  9. Carrel S, N de Tribolet, JP Mach: Expression of neuroectodermal antigens common to melanomas, gliomas and neuroblastomas. Acta Neuropathol (Berl) 57 (1982) 158–164

    Google Scholar 

  10. Coakham HB, PL Kornblith, EA Qundlen, LA Pollock, W Wood, LC Hartnett: Autologous humoral response to human gliomas and analysis of certain cell surface antigens: in vitro study with the use of microcytotoxicity and immune adherence. J Natl Cancer Inst 64 (1980) 223–233

    Google Scholar 

  11. Coakham HB, JA Garson, JT Kemshead, EZ Harper, B Brownell: Monoclonal antibodies to uncultured human astrocytomas. J Neuroimmunol 3 (1982) 238

    Google Scholar 

  12. Köhler G, C Milstein: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (Lond) 256 (1975) 495–497

    Google Scholar 

  13. Kornblith PL, FC Dohan, W Wood, BO Whitman: Human astrocytoma: serum-mediated immunologic response. Cancer 32 (1974) 1512–1519

    Google Scholar 

  14. Leong SPL, PD Noguchi, RE Cunningham, T Takami, JA Roth: Heterogenous expression of a murine B16 melanoma-associated antigen correlates with cell cycle. Cancer Immunol Immunother 24 (1987) 106–112

    Google Scholar 

  15. Levy NL, MS Mahaley, ED Day: In vitro demonstration of cell-mediated immunity to human brain tumors. Cancer Res 32 (1972) 477–482

    Google Scholar 

  16. Mahaley MS: Immunological aspects of the growth and development of human and experimental brain tumors. In: The Experimental Biology of Brain Tumors. Thomas, Springfield 1972

    Google Scholar 

  17. Martin B: Bindungseigenschaften monoklonaler Antikörper gegen Gliome des Menschen in vitro und in vivo. Vet. med. Dissertation, Universität München 1988

  18. McComb RD, C Wirkstrand, MA Bourdon, S Bigner, D Bigner: Antigenic heterogeneity of human malignant gliomas demonstrated by reactivity with 10 monoclonal antibodies. J Neuropathol Exp Neurol 42 (1984) 308

    Google Scholar 

  19. de Muralt B, N de Tribolet, AC Diserens, D Stavrou, JP Mach, S Carrel: Phenotyping of 60 cultured human gliomas and 34 other neuroectodermal tumors by means of monoclonal antibodies against glioma, melanoma and HLA-DR antigens. Eur J Cancer Clin Oncol 21 (1985) 207–216

    Google Scholar 

  20. Neuwelt EA, WK Clark: CNS tumor immunology. In: Clinical Aspects of Neuroimmunology. Williams-Wilkins, Baltimore 1978

    Google Scholar 

  21. Nowell P: The clonal evolution of tumor cell populations. Acquired genetic lability permits stepwise selections of variant sublines and underlies tumor progression. Science 194 (1976) 23–28

    Google Scholar 

  22. Olsson L: Phenotypic diversity of malignant cell populations: Molecular mechanisms and biological significance. Cancer Rev 3 (1986) 91–114

    Google Scholar 

  23. Reichner H: Zur Frage der serologischen Unterscheidung zwischen infiltrierendem Neoplasma (Gliom) und normalem Gewebe des Hirns. Z Immunitätsforsch 80 (1933) 86–95

    Google Scholar 

  24. Roholl PJM, ASH de Jong, FCS Ramaekers: Application of markers in the diagnosis of soft tissue tumours. Histopathol 9 (1985) 1019–1035

    Google Scholar 

  25. Schnegg JF, AC Diserrens, S Carrel, RS Acolla, N de Tribolet: Human glioma associated antigens detected by monoclonal antibodies. Cancer Res 41 (1981) 1209–1213

    Google Scholar 

  26. Schold SC, D Bigner: Treatment of five subcutaneous human glioma tumor lines in athymic mice with carmustine, procarbazine and mithramycin. Cancer Treat Rep 67 (1983) 811–819

    Google Scholar 

  27. Seeger RC, HM Rosenblatt, K Imai, S Ferrone: Common antigenic determinants on human melanoma, glioma, neuroblastoma and sarcoma cells defined by monoclonal antibodies. Cancer Res 41 (1981) 2714–2717

    Google Scholar 

  28. Shapiro JR, WA Yung, GA Basler, WR Shapiro: Heterogenous response to chemotherapy of human gliomas grown in nude mice and as clones in vitro. Cancer Treat Rep 65 (1981) 55–59

    Google Scholar 

  29. Stavrou D: Mögliche immunologische Aspekte bei experimentellen neurogenen Tumoren. Zbl allg Path 120 (1976) 535

    Google Scholar 

  30. Stavrou D, AP Anzil, W Weidenbach, H Rodt: Immunofluorescence study of lymphocytic infiltration in gliomas. Identification of T-lymphocytes. J Neurol Sci 33 (1977) 272–282

    Google Scholar 

  31. Stavrou D, AP Anzil, H Elling: Tumor specific fluorescent and complement-dependent cytotoxic antibodies in the serum of rats with chemically induced brain gliomas. Acta Neuropathol (Berl) 43 (1978) 111–117

    Google Scholar 

  32. Stavrou D, M Hulten, AP Anzil, Th Bilzer: The humoral antibody response of rats immunized with chemically modified syngeneic brain cells and glioma cells. Int J Cancer 26 (1980) 629–637

    Google Scholar 

  33. Stavrou D, M Hulten, Th Bilzer: Chemical modification and antigenicity of glioma cells. Acta Neuropathol (Berl) Suppl VII (1981) 75–78

    Google Scholar 

  34. Stavrou D, Ch Süss: Hybridomas producing monoclonal antibodies against chemically induced gliomas. J Neuroimmunol 3 (1982a) 241

    Google Scholar 

  35. Stavrou D, Th Bilzer, M Hulten, K Zänker, AP Anzil, K Haglid, E Dahme: Immunological aspects of experimental brain tumors. Anticancer Res 2 (1982b) 151–156

    Google Scholar 

  36. Stavrou D, Ch Süss, Th Bilzer, U Kummer, N de Tribolet: Monoclonal antibodies reactive with glioma cell lines derived from experimental brain tumors. Eur J Cancer Clin Oncol 19 (1983) 1439–1449

    Google Scholar 

  37. Stavrou D, W Mellert, Th Bilzer, R Senekowitsch, E Keiditsch, P Mehraein: Radioimmunodetection of gliomas by administration of radiolabelled monoclonal antibodies. Anticancer Res 5 (1985) 147–156

    Google Scholar 

  38. Stavrou D, H Glässner, Th Bilzer, R Senekowitsch, E Keiditsch, P Mehraein: Radioimaging of experimental glioma grafts using F(ab′)2 fragments of monoclonal antibodies. Anticancer Res 6 (1986a) 897–904

    Google Scholar 

  39. Stavrou D, W Mellert, U Mellert, E Keiditsch, K Bise, P Mehraein: Growth inhibition of experimental glioma grafts by monoclonal antibody treatment. J Cancer Res Clin Oncol 112 (1986b) 111–118

    Google Scholar 

  40. Stavrou D, E Keiditsch, F Schmidberger, K Bise, I Funke, W Eisenmenger, R Kurrle, B Martin, U Stocker: Monoclonal antibodies against human astrocytomas and their reactivity pattern. J Neurol Sci 80 (1987a) 205–220

    Google Scholar 

  41. Stavrou D: Immunological aspects of brain tumors. In: Grundmann, E (ed): Cancer Campain Vol 10 Experimental Neurooncology, Brain Tumor and Pain Therapy. G. Fischer, Stuttgart—New York 1987b

    Google Scholar 

  42. Stavrou D, B Martin, U Stocker, V Kallmeyer, Th Bilzer, K Bise, E Keiditsch: Radioimmunoimaging of human glioma xenografts by external scintigraphy. Clin Neuropathol 7 (1988) 212–213

    Google Scholar 

  43. de Tribolet N, S Carrel: Human glioma tumourassociated antigens. Cancer Immunol Immunother 9 (1980) 207–211

    Google Scholar 

  44. Wikstrand CJ, DD Bigner: Expression of human fetal brain antigens by human tumors of neuroectodermal origin as defined by monoclonal antibodies. Cancer Res 42 (1982) 267–275

    Google Scholar 

  45. Wikstrand C, S Bigner, D Bigner: Demonstration of complex antigenic heterogeneity in a human glioma cell line and eight derived clones by specific monoclonal antibodies. Cancer Res 43 (1983) 3327–3334

    Google Scholar 

  46. Wikstrand C, F Grahmann, R McComb, D Bigner: Antigenic heterogeneity of human anaplastic gliomas and glioma-derived cell lines defined by monoclonal antibodies. J Neuropathol Exp Neurol 44 (1985) 229–241

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neuropathology, University of Hamburg, University Hospital Eppendorf, Hamburg, West Germany

    Dimitrios Stavrou

Authors
  1. Dimitrios Stavrou
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stavrou, D. Monoclonal antibodies in neuro-oncology. Neurosurg. Rev. 13, 7–18 (1990). https://doi.org/10.1007/BF00638887

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00638887

Keywords

Search

Navigation